Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [MJF-R11 (75-1)] to LRRK2 (phospho S955) - BSA and Azide free
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Product nameAnti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] - BSA and Azide free
See all LRRK2 primary antibodies
DescriptionRabbit monoclonal [MJF-R11 (75-1)] to LRRK2 (phospho S955) - BSA and Azide free
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse
Synthetic peptide within Human LRRK2 (phospho S955). The exact sequence is proprietary.
Database link: Q5S007
ab172380 is the carrier-free version of ab169521 This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Ab172380 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
This antibody was developed with support of The Michael J. Fox Foundation (MJFF) with the assistance of a consortium of investigators to help accelerate LRRK2 research.
LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a multi-domain protein belonging to the ROCO family of proteins that contains a kinase and GTPase domain among its many protein interaction domains. LRRK2 is mutated in a significant number of Parkinson's disease(PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. The most common mutation replaces glycine 2019 with a serine that results in increased LRRK2 kinase activity. This indicates that inhibitors of LRRK2 kinase activity might be of therapeutic benefit for the treatment of Parkinson’s disease and has stimulated much activity in this field of research. Based upon mass spectrometry findings, a number of other residues within LRRK2 have also been found to be phosphorylated as well.
It is of note that phosphorylation of Serine 955 is not thought to be the result of autophosphorylation of the kinase though currently, the physiological relevance of these phospho-sites is not clear. Thus with the generation of this phospho-specific antibody, it is MJFF's hope that investigators may have at hand a critical tool to assist in their research endeavors that might thereby lend further clarity to the field of LRRK2 and its role in PD pathogenesis.
Acknowledgements: The Michael J. Fox Foundation would like to acknowledge the assistance of the following laboratories and individuals, whose input, guidance and assistance in testing all phospho specific LRRK2 antibodies was critical:
• The Laboratory of Dr. Dario Alessi (University of Dundee) - Paul Davies, PhD
• The Laboratory of Dr. Mark Cookson (National Institute on Aging) - Alexandra Beilina, PhD
• The Laboratory of Dr. Johannes Gloeckner (Helmholtz Zentrum Munchen)
• The Laboratory of Dr. Takeshi Iwatsubo (University of Tokyo) - Genta Ito, PhD
• The Laboratory of Dr. Jeremy Nichols (The Parkinson's Institute)
• The Laboratory of Dr. Andrew West (University of Alabama)
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze.
Storage bufferConstituent: PBS
Concentration information loading...
PurityProtein A purified
Clone numberMJF-R11 (75-1)
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab172380 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. Predicted molecular weight: 286 kDa.
Use at an assay dependent concentration. Predicted molecular weight: 286 kDa.
FunctionPositively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease.
Tissue specificityExpressed in the brain. Expressed in pyramidal neurons in all cortical laminae of the visual cortex, in neurons of the substantia nigra pars compacta and caudate putamen (at protein level). Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
Involvement in diseaseParkinson disease 8
Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.
Contains 12 LRR (leucine-rich) repeats.
Contains 1 protein kinase domain.
Contains 1 Roc domain.
Contains 7 WD repeats.
DomainThe seven-bladed WD repeat region is critical for synaptic vesicle trafficking and mediates interaction with multiple vesicle-associated presynaptic proteins.
The Roc domain mediates homodimerization and regulates kinase activity.
Cellular localizationMembrane. Cytoplasm. Perikaryon. Mitochondrion. Golgi apparatus. Cell projection, axon. Cell projection, dendrite. Endoplasmic reticulum. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane. Endosome. Lysosome. Mitochondrion outer membrane. Mitochondrion inner membrane. Mitochondrion matrix. Predominantly associated with intracytoplasmic vesicular and membranous structures (By similarity). Localized in the cytoplasm and associated with cellular membrane structures. Predominantly associated with the mitochondrial outer membrane of the mitochondria. Colocalized with RAB29 along tubular structures emerging from Golgi apparatus. Localizes in intracytoplasmic punctate structures of neuronal perikarya and dendritic and axonal processes.
- Information by UniProt
- augmented in rheumatoid arthritis 17 antibody
- AURA17 antibody
- Dardarin antibody
Lanes 1-2 : Anti-DDDDK tag antibody
Lanes 3-4 : Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] (ab169521) at 1/2000 dilution (Anti-DDDDK tag antibody)
Lanes 5-6 : Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] (ab169521) at 1/10000 dilution (Anti-DDDDK tag antibody)
Lanes 1 & 3 & 5 : HEK293T cells stably expressed with wild-type DDDDK-LRRK2
Lanes 2 & 4 & 6 : HEK293T cells stably expressed with mutant DDDDK-LRRK2
Predicted band size: 286 kDa
This data was developed using ab169521, the same antibody clone in a different buffer formulation.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab172380 has not yet been referenced specifically in any publications.